IMMUWIN - A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage HCC

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513950-32-00

Acronym

IMMUWIN

Enrollment

Registered

2024-09-03

Start date

2020-12-15

Completion date

Unknown

Last updated

2025-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermediate stage hepatocellular carcinoma (HCC)

Brief summary

Objective response rate (ORR) [according to RECIST 1.1] after 6 months.

Detailed description

PFS, OS, Safety (AEs, impact of liver function, use of subsequent therapies), ORR as BOR during therapy, ORR within 6 months for patients who received single treatment of TACE/SIRT, ORR within 6 months for patients who received additional treatment of TACE/SIRT, QoL

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGTREMELIMUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR) [according to RECIST 1.1] after 6 months.	—

Secondary

Measure	Time frame
PFS, OS, Safety (AEs, impact of liver function, use of subsequent therapies), ORR as BOR during therapy, ORR within 6 months for patients who received single treatment of TACE/SIRT, ORR within 6 months for patients who received additional treatment of TACE/SIRT, QoL	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026